H.C. Wainwright lowered the firm’s price target on Fate Therapeutics to $5 from $7 and keeps a Buy rating on the shares following the Q1 report.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FATE:
- Fate Therapeutics’ Reporting Strategy: A Double-Edged Sword for Investor Confidence and Share Stability
- Fate Therapeutics price target lowered to $4 from $7 at Piper Sandler
- Fate Therapeutics price target lowered to $5 from $7 at Wedbush
- Fate Therapeutics price target lowered to $9 from $11 at Canaccord
- Fate Therapeutics reports Q1 EPS (47c), consensus (49c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue